NCT01231399View on ClinicalTrials.gov

Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Adenocarcinoma of the EsophagusAdenocarcinoma of the Gastroesophageal JunctionDiffuse Adenocarcinoma of the StomachIntestinal Adenocarcinoma of the StomachMixed Adenocarcinoma of the StomachRecurrent Esophageal CancerRecurrent Gastric CancerStage IV Esophageal CancerStage IV Gastric Cancer
Interventions
DRUG

fluorouracil

Given IV

DRUG

leucovorin calcium

Given IV

DRUG

oxaliplatin

Given IV

DRUG

everolimus

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

immunohistochemistry staining method

Correlative studies

GENETIC

microarray analysis

Correlative studies

Trial Locations (3)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

91010

City of Hope Medical Center, Duarte

91030

South Pasadena Cancer Center, South Pasadena

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT01231399 - Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer | Biotech Hunter | Biotech Hunter